Back to Search
Start Over
P962: CHANGE IN SOLUBLE BCMA LEVEL MAY BE A SURROGATE MARKER OF EARLY RESPONSE TO THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): PRELIMINARY RESULTS FROM A PHASE I STUDY OF CEVOSTAMAB.
- Source :
- HemaSphere; 2022 Supplement 3, Vol. 6, p852-853, 2p
- Publication Year :
- 2022
Details
- Language :
- English
- ISSN :
- 25729241
- Volume :
- 6
- Database :
- Complementary Index
- Journal :
- HemaSphere
- Publication Type :
- Academic Journal
- Accession number :
- 175293345
- Full Text :
- https://doi.org/10.1097/01.HS9.0000846716.90763.d0